A detailed history of Paradigm Biocapital Advisors LP transactions in Legend Biotech Corp stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 1,203,308 shares of LEGN stock, worth $48.3 Million. This represents 2.16% of its overall portfolio holdings.

Number of Shares
1,203,308
Previous 1,982,006 39.29%
Holding current value
$48.3 Million
Previous $111 Million 52.06%
% of portfolio
2.16%
Previous 4.17%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$39.5 - $57.22 $30.8 Million - $44.6 Million
-778,698 Reduced 39.29%
1,203,308 $53.3 Million
Q1 2024

May 15, 2024

BUY
$55.06 - $69.99 $4.81 Million - $6.11 Million
87,362 Added 4.61%
1,982,006 $111 Million
Q4 2023

Feb 14, 2024

SELL
$57.25 - $69.74 $7.49 Million - $9.12 Million
-130,836 Reduced 6.46%
1,894,644 $114 Million
Q3 2023

Nov 14, 2023

BUY
$63.16 - $76.5 $13.9 Million - $16.8 Million
219,763 Added 12.17%
2,025,480 $136 Million
Q2 2023

Aug 14, 2023

BUY
$46.28 - $75.01 $13.7 Million - $22.2 Million
295,393 Added 19.56%
1,805,717 $125 Million
Q1 2023

May 15, 2023

BUY
$43.42 - $57.37 $19.8 Million - $26.1 Million
455,454 Added 43.18%
1,510,324 $72.8 Million
Q4 2022

Feb 14, 2023

SELL
$38.8 - $55.46 $842,774 - $1.2 Million
-21,721 Reduced 2.02%
1,054,870 $52.7 Million
Q3 2022

Nov 14, 2022

BUY
$38.15 - $57.1 $3.74 Million - $5.6 Million
97,995 Added 10.01%
1,076,591 $43.9 Million
Q2 2022

Aug 15, 2022

BUY
$33.54 - $55.0 $4.93 Million - $8.08 Million
146,868 Added 17.66%
978,596 $53.8 Million
Q1 2022

May 16, 2022

BUY
$31.02 - $48.18 $13.8 Million - $21.5 Million
445,761 Added 115.49%
831,728 $30.2 Million
Q4 2021

Feb 14, 2022

BUY
$41.14 - $56.98 $15.9 Million - $22 Million
385,967 New
385,967 $18 Million

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.73B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Paradigm Biocapital Advisors LP Portfolio

Follow Paradigm Biocapital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.